Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the commencement of a toxicology safety study of its lead nanoparticle
MELBOURNE, Australia, Dec. 17, 2018 /PRNewswire/ — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, and Planet
Pre-clinical data on Imagion Biosystems’ MagSense HER2+ cancer detection platform have shown: specific binding and detection of HER2+ tumor cells in vitro specific detection of
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
